Liarozole-fumarate Enhances Antiproliferative Activity of Retinoic Acid in Breast Cancer Cells
Author Information
Author(s): J Van heusden, W Wouters, FCS Ramaekers, MDWG Krekels, L Dillen, M Borgers, G Smets
Primary Institution: University of Maastricht; Janssen Research Foundation
Hypothesis
Does liarozole-fumarate enhance the antiproliferative activity of all-trans-retinoic acid (ATRA) and its catabolites in MCF-7 human breast cancer cells?
Conclusion
Liarozole-fumarate enhances the antiproliferative activity of ATRA and its catabolites but not of its stereoisomers in MCF-7 cells.
Supporting Evidence
- Liarozole-fumarate significantly enhanced the antiproliferative activity of ATRA and its catabolites.
- Liarozole-fumarate did not enhance the activity of ATRA stereoisomers.
- MCF-7 cells showed a BrdU labelling index of 25.2 ± 1.4% under control conditions.
- Statistical analysis showed significant differences at p<0.01.
Takeaway
Liarozole-fumarate helps a cancer treatment work better by stopping the body from breaking down a medicine called retinoic acid too quickly.
Methodology
MCF-7 cells were treated with liarozole-fumarate and various concentrations of ATRA and its catabolites, and cell proliferation was measured using BrdU incorporation.
Limitations
The study primarily focuses on MCF-7 cells, which may not represent all breast cancer types.
Participant Demographics
MCF-7 human breast cancer cells were used in the study.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Want to read the original?
Access the complete publication on the publisher's website